Trial Type: Breast Cancer

A Phase 1 Study of NM32-2668 (Anti ROR1/Anti CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)

A Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

A011801 Compass HER2RD: a double-blinded, phase III, randomized trial of T-DM1 compared with T-DM1 and Tucatinib

LS-P-COASTAL: Phase I study of inhibitor of SIRPa-CD47 axis with trastuzumab and deruxtecan for HER2+ solid tumors and cohort for HER2 low breast cancer

LS-P-Poppy: First-in-class antibody-drug conjugate (ADC) targeting fibronectin (PYX-201) for solid tumors

A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive Breast Cancer

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy